QuickLinks -- Click here to rapidly navigate through this document

SCHEDULE 14A
(RULE 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act
of 1934 (Amendment No. 1)

Filed by the Registrant ý
Filed by a Party other than the Registrant o

Check the appropriate box:

o   Preliminary Proxy Statement   o   Confidential for Use of the Commission Only
ý   Definitive Proxy Statement       (as permitted by Rule 14a-6(e)(2))
o   Definitive Additional Materials        
o   Soliciting Material under Rule 14a-12        

Medtronic, Inc.

(Name of Registrant as Specified In Its Charter)

    

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
         
Payment of Filing Fee (Check the appropriate box):

ý

 

No fee required.
o   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

1)

 

Title of each class of securities to which transaction applies:
      

    2)   Aggregate number of securities to which transaction applies:
      

    3)   Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
      

    4)   Proposed maximum aggregate value of transaction:
      

    5)   Total fee paid:
     


o

 

Fee paid previously with preliminary materials.

o

 

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

 

 

1)

 

Amount Previously Paid:
    

    2)   Form, Schedule or Registration Statement No.:
    

    3)   Filing Party:
    

    4)   Date Filed:
    


        Explanatory Note:    In the Medtronic Proxy Statement filed with the Securities and Exchange Commission on July 19, 2002 and dated as of July 22, 2002, there was an error in the Executive Compensation table that has now been corrected, as reflected below. The error appeared in the disclosure regarding compensation paid to Keith E. Williams during Medtronic's fiscal year ended April 30, 2000. The Proxy Statement filed on July 19, 2002 indicated that Mr. Williams received a cash bonus during fiscal 2000 of $246,758 when, in fact, Mr. Williams elected to receive stock options in lieu of that cash bonus payment under the Management Incentive Plan. As a result, we have corrected the disclosure with respect to Mr. Williams' compensation for fiscal 2000 as set forth in the table below and we have corrected the disclosure in Footnote 2 to the Executive Compensation Table to give effect to that correction, also as set forth below. The number that appears in the "Securities Underlying Options / SARs" column for fiscal 2000 for Mr. Williams was and is correct in the Proxy Statement filed on July 19, 2002 and gives effect to his election to receive stock options in lieu of his cash bonus payment under the Management Incentive Plan. There are no other revisions, corrections or amendments to the Medtronic Proxy Statement filed on July 19, 2002.



EXECUTIVE COMPENSATION

        The following table sets forth the cash and non-cash compensation for each of the last three fiscal years ended April 26, 2002, April 27, 2001 and April 30, 2000 awarded to or earned by the Chief Executive Officer, each of the other four most highly compensated executive officers of Medtronic, and Dr. Nelson, who would have been in this group had he not retired before fiscal year end.


Summary Compensation Table

 
   
   
   
   
  Long-Term Compensation
   
 
   
  Annual Compensation
  Awards
  Payouts
   
Name and Principal Position

  Fiscal
Year

  Salary
($)(1)

  Bonus
($)(2)

  Other Annual
Compensation
($)(3)

  Restricted
Stock
Awards
($)(4)

  Securities
Underlying
Options/SARs
(#)(2)(5)

  LTIP
Payouts
($)(5)

  All Other
Compensation
($)(6)

Keith E. Williams
Senior Vice President & Chief Quality Officer
  2002
2001
2000
  358,595
320,008
275,000
  244,203
207,704
 

 

  98,062
46,700
80,735
 
95,420
  22,598
21,264
19,769

(2)
"Bonus" column does not include cash bonus payments that Dr. Nelson and Messrs. Ryan and Williams elected to forgo in order to receive stock options granted in lieu of all of their cash bonus compensation under the Management Incentive Plan. The cash bonus payments forgone by Dr. Nelson and Messrs. Ryan and Williams, respectively, were: fiscal 2002, $292,461 by Mr. Ryan; fiscal 2001, $408,169 by Dr. Nelson and $255,225 by Mr. Ryan; fiscal 2000, $490,098 by Dr. Nelson, $275,373 by Mr. Ryan and $246,758 by Mr. Williams. These stock options are included in the "Securities Underlying Options/SARs" column. See "Report of the Compensation Committee on Fiscal 2002 Executive Compensation—Stock Option Exchange Program" and "Option/SAR Grants in Last Fiscal Year," below.



QuickLinks

EXECUTIVE COMPENSATION
Summary Compensation Table